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complexity of care 
in adulthood

REASONS FOR NEW TARGETS?
Lesser gains above BMI 
22 (women), 23 (men)
Advantages reduce as 
BMI reaches 30
Adults
LONGITUDINAL CHANGES  IN BMI 
n=204
N.J. Greig, H. White, H.K. Chadwick, A. Cartwright, D.G. Peckham
Cardiovascular risk in an adult CF population : a 9 year retrospective analysis 
ENERGY & MACRONUTRIENT TARGETS 
DIETARY EMPHASIS ON FATS
Fat 35-40% of 
intake
DIFFERING ADULT POPULATIONS
N.J. Greig, H. White, H.K. Chadwick, A. Cartwright, D.G. Peckham
Cardiovascular risk in an adult CF population : a 9 year retrospective analysis 
WHAT TYPES OF FAT?
 Greater longevity
 Vascular endothelial dysfunction 
shown in children with CF (2013)
 Ischaemic heart disease reported in 
CF(2010)
 Greater emphasis on 
polyunsaturated and mono-
unsaturated fats
 May also improve essential 
fatty acid status
 CF Trust (2016) &
 ESPEN-ESPGHAN-ECFS guidelines (2016)
HIGH PROTEIN….?
 Low muscle mass is 
consistently associated with 
pulmonary decline
 Protein digestion capacity is 
severely impaired in CF
Protein 
No evidence based recommendations for daily protein intake 
for CF (CF Trust 2016)
20% energy ESPEN-ESPGHAN-ECFS (2016)
0.83g protein/kg
SHEIKH ET AL, 2014
 High likelihood of normal 
lung function, targeting BMI 
z-score > 0
 Improved further, by 
targeting  LBM z-score >0
SUPPLEMENTS – WHICH ONES?
Complete 
supplement – small 
volume (125ml)
Complete 
supplement – 200ml 
volume
Fat free supplement 
– no enzymes 
required
High calorie, high fat 
supplement (600kcal/240ml 
drink)
ORAL CALORIE SUPPLEMENTS – COCHRANE REVIEW (2014)
 Limited trials
 Kalnins et al (2005)
 21 %, 28% intake from oral calorie supplements at 1 and 3 
months (mean 1.6 cans/day)
 No change in weight or height z-score
 Hanning et al (2005)
 25 % of EAR energy intake from supplements additional to 
normal diet
 No change in weight or height z-score at 6 months
 Poustie et al (2006) Oral protein energy supplements for 
children with cystic fibrosis: CALICO multicentre randomised 
controlled trial 
 No improvements in children with cystic fibrosis who were 
moderately malnourished
ENTERAL TUBE FEEDING FOR INDIVIDUALS WITH  CF: CF 
FOUNDATION EVIDENCE INFORMED GUIDELINES (2016)
 ETF can improve age dependent 
anthropometrics
 ETF is given as a continuous 
overnight infusion
 Cannot recommend ETF to 
improve or stabilise lung function
 Recommends against FEV1 being 
used as a contraindication to PEG 
or G-Tube placement
ENTERAL TUBE FEEDING - WHAT ARE THE LATEST KEY 
DOCUMENTS?
WHAT ELSE TO CONSIDER IN OPTIMISING NUTRITION
 High energy/high protein diet
 Oral dietary supplements
 Enteral tube feeding
 Enzyme therapy
 Vitamin supplementation (A,D,E,K)
 Co-morbidities – cystic fibrosis 




CYSTIC FIBROSIS RELATED DIABETES - THE BASIC DEFECT
 Pancreatic ß cell dysfunction, fatty infiltration and 
fibrosis
 Causes decreased but not absolute insulin deficiency
 Diabetic ketoacidosis is rare
 Develops insidiously
 Patients may be asymptomatic
 Often first presents where insulin resistance is 
increased
 Acute pulmonary infection
 Chronic severe lung disease
 Glucocorticoid therapy
 Immunosuppression regimens (post-transplant)
Acinar cells -digestive 
enzymes
Beta cells -insulin
AT WHAT STAGE DOES IT BEGIN TO OCCUR
CF Foundation Patient 
Registry Data, 2014
o Progressive with age
o Annual screening for CFRD ≥ 10 years, 
using OGTT
o Poor sensitivity of HBA1c
CYSTIC FIBROSIS RELATED DIABETES
CHANGING FOCUS
CRUCIAL CHANGES TO CARE
 Annual screening using the oral glucose 
tolerance test
 Early instigation of insulin therapy
NUTRITIONAL GAINS ASSOCIATED WITH INSULIN TREATMENT
3 months 6 months 1 year 2 year
Moran et al, 
(2009)
2%   BMI
White et al 
(2009)
3.3%    BMI 5.9 %   BMI
Nousia
Avanitarkis et al, 
(2001)
16.6%   BMI
Rafii et al, (2005) 2.4%   BMI 6.9%    BMI
DIETARY RECOMMENDATIONS … CHANGE?
Update on cystic fibrosis related diabetes Kelly A, Moran A [Journal of 
Cystic fibrosis 2013:12;318-331]
 Consuming simple CHO in combination with complex CHO, 
protein and fat may limit the glucose excursion
CF Trust Nutritional management of Cystic Fibrosis (2016)
 Type I /II advice inappropriate
 Some people may be taught CHO counting
 If they do not CHO count regular meals should be encouraged  




should be done 
conservatively 
- to avoid 
hypoglycemia. 
LEWIS ET AL (2015)
DIABETES – RELATED MORTALITY IN ADULTS WITH CYSTIC FIBROSIS
Diabetes related mortality in adults with cystic fibrosis: 
Role of genotype and sex
Am J Resp & Critical Care Med 2015:191(2);194-200
In 5th decade 83% women and 64% men with a severe 
genotype had CFRD






















Requirements for normal 
bone mineralisation
Adequate bone mass (especially during the growth 
spurt)
Protein osteoid formation
Vitamin D Calcium absorption and 
phosphate utilisation
Calcium, phosphate and 
Magnesium
Bone calcification and 
mineralisation
Vitamin K Carboxylation of osteocalcin
RISK FACTORS FOR VITAMIN D DEFICIENCY IN CF
 Reduced absorption Lark et al, 2001
 Inadequate supplementation
 Non adherence to therapy
 Reduced stores due to depleted fat mass
 Reduced sunlight exposure because of illness and medications
 Low vitamin D binding proteins Speeckaert et al, 2008
 Mg deficiency causes functional vitamin D deficiency (renal 25 OHD to 1,25(OH)2D)
VITAMIN D INSUFFICIENCY PERSISTS IN CF
Paediatric Insufficiency/deficiency
Canada Grey et al, 2008 88% insufficient
USA Green et al 2008 46% insufficient
France Sermet-Gaudelus et al, 2008 90% insufficient
UK Conway et al., 2008 78% insufficient
15.0% deficient
Russia Asherova et al, 2008 41.7% insufficient
16.6% deficient
TRENDS IN BMD 
STATUS
 Vitamin D intakes had 
increased by 53%
 Contributing factors 
may include steroid use, 
low BMI, inadequate 
calcium and vitamin D 
intake, and poor 
nutrient absorption, as 
well as effects of gene 
mutation on bone cells
VITAMIN D SUPPLEMENTATION
 > 1 years 1,000-5,000 IU Vitamin D3/day 
 Aiming for minimum of 50nmol/L
ECFS, 2011
CONTINUED DEBATE
Target serum level >20 or >30ng/ml (50-75nmol/l) –
mixed guidance 
Timing (Possible improved absorption with food and 
enzymes)
Vitamin D2 or Vitamin D3? - Vitamin D3 
(Cholecalciferol)
Intervals (no evidence for bolus versus daily dosing)
UV lamps (no recommendation)
GREATER CERTAINTY…
Vit D measured by total serum 25(OH) D as it is associated 
with health outcomes, is the primary circulating form of Vit D 
and accounts for Vit D from diet & sunlight
Assess during the winter months (winter levels shown to be 
only 70% of summer values)
Repeat intervals following changes in treatment should be 
undertaken at 3 months
CALCIUM
 Should be assessed at least 
annually (ESPEN-ESPGHAN-ECFS 
Guidelines)
 Daily calcium intakes should be at 
a minimum to achieve dietary 
intake recommended by the EFSA






11-17 years 1150mg (1300mg 9-18yrs)
18-25 years 1000mg
>25 years 950mg
Calcium intake for people with CF: 
recommendations guided by EFSA
VITAMIN K
 Sub clinical as assessed by increased 
PIVKA II- almost universal in CF Conway 
et al, 2005; Rashid et al, 1999; Becker et 
al, 1997; Wilson et al,1997
 Increased % of undercarboxylated
osteocalcin (Glu-Oc) Fewtrell et al, 2008; 
Grey et al, 2008; Nicolaidou et al, 2006; 
Conway et al, 2005; Aris et al, 2003
 Associated with increased bone turnover
 Reduced markers of bone mineral accrual
ECFS, 
2011 Initial scan age 8-10 years
Normal LS Z score
Rescan every 5yrs
LS Z score -1 to -2
Rescan every 2yrs
LS Z score <-2
“CF related low 
BMD”
Rescan every yr
European Cystic Fibrosis Bone Mineralisation Guidelines
‘If height is ≥1 SD below age and sex matched healthy 
controls, BMD Z scores should be adjusted for height or 
statural age to avoid overestimating deficits in BMD in people 
with short stature’
Stress the importance of serial height adjusted measurements 
Sermet-Gaudelus et al, 2011
SUMMARY
 Greater complexity of nutritional management and emergence of new therapies
 Diet, oral supplementation, enteral tube feeding
 Pancreatic enzyme therapy introduction 
 Vitamin Supplementation (Vitamin A,D, E, K)
 Cystic fibrosis related diabetes, osteoporosis, management of pregnancy, post-
transplantation…. and others
 Improvements in nutritional status over the last 10 years aligned with earlier and 
more aggressive interventions across all aspects of nutritional management
 …..The future for our adult populations?
